- Open Access
IL-4Rα blockade reduces influenza-associated morbidity in a murine model of allergic asthma
Respiratory Research volume 22, Article number: 75 (2021)
Asthma was identified as the most common comorbidity in hospitalized patients during the 2009 H1N1 influenza pandemic. We determined using a murine model of allergic asthma whether these mice experienced increased morbidity from pandemic H1N1 (pH1N1) viral infection and whether blockade of interleukin-4 receptor α (IL-4Rα), a critical mediator of Th2 signalling, improved their outcomes.
Male BALB/c mice were intranasally sensitized with house dust mite antigen (Der p 1) for 2 weeks; the mice were then inoculated intranasally with a single dose of pandemic H1N1 (pH1N1). The mice were administered intraperitoneally anti-IL-4Rα through either a prophylactic or a therapeutic treatment strategy.
Infection with pH1N1 of mice sensitized to house dust mite (HDM) led to a 24% loss in weight by day 7 of infection (versus 14% in non-sensitized mice; p < .05). This was accompanied by increased viral load in the airways and a dampened anti-viral host responses to the infection. Treatment of HDM sensitized mice with a monoclonal antibody against IL-4Rα prior to or following pH1N1 infection prevented the excess weight loss, reduced the viral load in the lungs and ameliorated airway eosinophilia and systemic inflammation related to the pH1N1 infection.
Together, these data implicate allergic asthma as a significant risk factor for H1N1-related morbidity and reveal a potential therapeutic role for IL-4Rα signalling blockade in reducing the severity of influenza infection in those with allergic airway disease.
The 2009 H1N1 influenza A pandemic strain (pH1N1, A(H1N1)pdm09) caused 18,500 deaths, over 12,500 of which were reported in the United States [1, 2]. However, studies have estimated the true impact of the pandemic to lie between 151,000–575,000 deaths worldwide . Generated through triple reassortment, the severity of this strain was due, in part, to a lack of pre-existing immunity in the population . Asthma, the most common risk factor for severe cases, was identified in 17–27% of hospitalized patients [4, 5]. With over 300 million people suffering from asthma worldwide, urgent action is needed to protect this population from highly virulent influenza A strains [6, 7].
Asthma is a complex disease that is associated with airway inflammation, remodeling, and hyper-reactivity. Allergic asthma, the most common endotype, is characterized by a predominant Th2-skewed phenotype, with patients exhibiting eosinophilia and elevated levels of interleukin (IL)-4, IL-5, and IL-13 in the airways and lung tissue [8,9,10,11,12]. IL-4 and IL-13 are thought to play an important role in asthma pathogenesis by inducing eotaxin (an eosinophil chemoattractant), increasing mucin glycoproteins (and causing mucous hyperplasia), and augmenting IgE-related hypersensitivity reactions [13,14,15]. Th2 cytokines have also been implicated in promoting viral exacerbations. For example, in an experimental rhinovirus infection model, patients with asthma were shown to develop a greater severity of lower respiratory tract symptoms and impaired lung function, which was associated with increased expression of IL-4, IL-5, and IL-13 in the bronchoalveolar lavage fluid (BALF) . Allergic asthma models have also demonstrated that IL-33, an upstream Th2 cytokine, may enhance influenza-induced exacerbations by dampening the expression of interferon (IFN)-β, a key antiviral mediator .
As the common receptor for both IL-4 and IL-13 signaling, blockade of IL-4 receptor alpha (IL-4Rα) has been touted as a method of alleviating asthma symptoms and severity . Murine asthma models have demonstrated a significant reduction in airway hyperresponsiveness, lung eosinophilia, and goblet cell metaplasia upon monoclonal antibody (mAb) blockade of IL-4Rα . Clinical trials using a humanized mAb targeting IL-4Rα have demonstrated up to 87% reduction in exacerbation rates and a 320 mL increase in FEV1 in patients with moderate to severe asthma [20, 21]. While the blockade of IL-4Rα has proven to be effective in reducing asthma severity, its clinical potential in ameliorating exacerbations of highly virulent influenza A infections has yet to be investigated. Here, we evaluated this using a murine model in which mice were sensitized to an extract from a common aeroallergen house dust mite (HDM) and intranasally infected with pH1N1. We found that HDM-sensitized mice had greater pH1N1-related morbidity which was alleviated by IL-4Rα mAb blockade. Our in vivo murine model results highlight the therapeutic potential of IL-4Rα-mediated therapies in asthmatic patients during influenza pandemics.
Detailed methods are provided in the Methods section in Additional file 1.
Male BALB/c mice (6–8 weeks old) were obtained from Jackson Laboratory (Bar Harbour, ME). Mice were housed in a specific pathogen-free environment with protocols approved by the Animal Care and Biosafety Committees of the University of British Columbia.
Acute house dust mite sensitization and pandemic H1N1 infection model
To create an allergic asthma model, mice were intranasally sensitized with 25 µg of HDM (Der p 1) delivered in 35 µL of phosphate-buffered saline (PBS). Control mice received PBS vehicle alone. Intranasal PBS or HDM instillations were performed 5 days per week for two consecutive weeks, followed by infection with pH1N1 (50 µL, 106.4 EID50/mL in chorioallantoic fluid (CAF)) or CAF) from non-infected eggs (vehicle control). Intranasal PBS or HDM instillations were continued for another week. Mice were sacrificed on day 8 post-pH1N1 infection (n = 10 per group, except n = 9 for HDM + pH1N1) or through two time-course studies (mice sacrificed either on days 0, 2, 4, 6, and 8 post-infection, or on days 0, 1, 3, 5, and 8 post-infection, n = 5 per group per day). Additional protocol details can be found in Fig. 1 and the Methods section in Additional file 1.
Prophylactic and therapeutic intervention designs
pH1N1-infected mice were intranasally exposed to PBS or HDM and received 2 mg of either anti-IL-4Rα (4-3) or IgG1 isotype control (4G8) mAb (Amgen, Seattle, WA) through an intraperitoneal route, as previously described [19, 22]. Anti-IL-4Rα immunotherapy was administered through either a prophylactic (on days 2, 7, and 12 days prior to and 3 days following pH1N1 infection) or a therapeutic strategy (on days 1 and 6 following pH1N1 infection), as outlined in Fig. 1 and the Methods section in Additional file 1.
Quantitative polymerase chain reaction (qPCR)
RNA was extracted from homogenized lung tissue. To quantify viral load, qPCR was performed on triplicates of RNA samples and viral standards ranging from 103 to 109 RNA copies. The expression of interferon stimulated genes (ISGs, i.e. OAS1, RIG-I, MX-1, IFITM3, ISG-15, and Viperin) were quantified using qPCR relative to the expression of the control gene GAPDH, and analyzed using the comparative Ct method (ΔΔCt) . See Additional details in the Methods section in Additional file 1.
Lung histopathology and morphometry
The left lung was inflated with 400 µL of 10% formalin and fixed for 24 h. Paraffin-embedded sections (3 µm) were stained with periodic acid-Schiff (PAS), and analyzed by applying a colour segmentation algorithm using Aperio ImageScope software (Leica Biosystems, Wetzlar, Germany). The basal border of the epithelium was traced, and the level of staining is expressed as the number of positive and strong positive pixels per µm of basement membrane. Airway epithelial thickness was measured in FFPE-mouse lung tissues and stained with PAS. Airway epithelial thickness was determined by normalizing the area enclosed between the apical surface and the basement membrane (BM) to the length of the BM . Sub-epithelial wall thickness was determined by normalizing the area enclosed between the BM and the adventitia to the length of the BM. All measurements were quantified using the Aperio ScanScope software. The histopathological assessment of tertiary lymphoid structures was performed as previously described . The fractional lymphoid tissue area was quantified on PAS-stained slides and normalized to total lung cross-sectional area and expressed as a percentage . Additional details on tissue sectioning can be found in the Methods section in Additional file 1.
Bronchoalveolar lavage fluid and plasma analysis
IL-4, IL-5, IFN-γ, eotaxin, IL-6, and IP-10 concentrations were measured by a multiplex assay, while IL-33 and IFN-β concentrations were determined by ELISA. Additional details on sample collection and processing can be found in the Methods section in Additional file 1.
D’Agostino-Pearson test was performed to determine normality prior to analysis. Weight was analyzed using a two-way ANOVA with a Bonferroni correction, while protein and gene expression data were analyzed using a two-way ANOVA with Sidak’s multiple comparisons test and the Mann–Whitney U test. All other data were analyzed using a two-tailed Student’s t-test (GraphPad Prism version 5.0, La Jolla, CA). Data are expressed as mean ± SEM, and P values < 0.05 were considered significant.
HDM-sensitized mice experience excessive weight loss following pH1N1 infection
To determine how underlying allergic sensitization and airway inflammation impact pH1N1-induced morbidity, mice were intranasally exposed to repeated doses of PBS or HDM, prior to and following intranasal inoculation with either pH1N1 or CAF (vehicle control). Weight loss was monitored daily as an indicator of disease severity. In CAF-exposed mice, HDM-sensitization alone failed to induce weight loss (Fig. 2). In contrast, pH1N1 infection induced significant (14.1% ± 3.4%) weight loss, which was exacerbated in HDM-sensitized mice (23.8% ± 1.7% weight loss) 7–8 days post-infection (Fig. 2a). HDM-sensitized mice also demonstrated higher immune cell infiltration into the airways, increased number of lymphoid structures and a higher concentration of total protein levels in lung homogenate supernatants on day 8 post-infection (Additional file 1: Fig. E7). Viral load was measured in homogenized lung tissue through a time-course experiment. HDM-sensitized mice exhibited higher viral titers beginning on day 4 and reaching over threefold higher levels by 8 days post-infection (see Additional file 1: Fig. E2A). The expression levels of interferon (IFN)-β and downstream interferon stimulated genes (ISGs) were also measured to assess host’s antiviral immune response. In addition to an elevated viral load, HDM-sensitized mice exhibited a fivefold reduction in the protein concentration of IFN-β in the airways (17.5 ± 7.2 pg/mL, vs. 3.4 ± 2.0 pg/ml in PBS-exposed mice, Fig. 2b). Furthermore, a dampened induction of several downstream ISGs, including MX1, OAS1, ISG-15, and viperin was observed on day 4 post-infection (Fig. 2d–j). See Additional file 1: Figs E2 and E3 for a complete time-course data of IFN-β and ISGs. We conclude that underlying allergic sensitization and airway inflammation exacerbate pathology associated with influenza virus infection.
HDM-sensitization induces greater Th2 cytokine production in the airways
Th1 and Th2 inflammatory mediators were measured through a time-course experiment to profile the HDM-induced airway inflammation. Analysis of the bronchoalveolar lavage fluid (BALF) revealed elevated levels of IL-4 on days 0, 1, 2, and 5 (Fig. 3a), and IL-5 on days 0 and 5 post-infection (Fig. 3b). IL-33, a cytokine upstream of IL-5 and IL-13 production, was measured as an early inducer of the Th2 response. IL-33 protein levels were significantly elevated in the lung tissue of HDM-sensitized mice on days 0, 2, and 8 post-infection (see Additional file 1: Fig. E4A). In contrast, the BALF levels of IFN-γ, a Th1 inflammatory mediator, were significantly lower in HDM sensitized mice on day 5 post-infection (see Additional file 1: Fig. E4B). We conclude that HDM-sensitization leads to a Th2 skewed immune response and a dampening of Th1 responses to influenza.
Prophylactic IL-4Rα blockade attenuates HDM-induced BALF eosinophilia
BALF inflammatory infiltrates and differential cell counts were evaluated from day 8 post-infection. HDM-sensitization induced a significant increase in BALF eosinophils (7.67% ± 4.29%, vs. 1.2% ± 1.2% in PBS-exposed mice, Fig. 4a). As expected, prophylactic treatment with a mAb targeting IL-4Rα signalling after the induction of HDM allergic airway inflammation attenuated this response, resulting in a 21.5-fold reduction in BALF eosinophils (1.24% ± 0.78% eosinophils, Fig. 4b and c). In addition, we found that both prophylactic and therapeutic treatment courses led to a 28.4-fold and an 8.6-fold reduction, respectively, in BALF levels of eotaxin, an early marker of eosinophil recruitment (Fig. 4d, e). Corresponding to an increased percentage of eosinophils, HDM-sensitization was associated with a reduction in the percentage of macrophages, which was rescued upon IL-4Rα mAb blockade through a prophylactic treatment (see Additional file 1: Figure E5G–I). No differences were observed in the percentage of neutrophils or lymphocytes (see Additional file 1: Figure E5A–F).
Prophylactic IL-4Rα blockade attenuates HDM-induced goblet cell metaplasia
Goblet cells were quantified through their distinct morphology on PAS stained histologic sections in order to assess the extent of goblet cell metaplasia induced by HDM sensitization. HDM-sensitized mice demonstrated increased epithelial and airway wall thickness compared to PBS-exposed mice in both pH1N1-infected and non-infected mice (Additional file 1: Figure E8). Goblet cell frequency was normalized to the length of the basal membrane to account for differences in airway size. HDM-sensitized mice displayed extensive PAS staining representative of goblet cell metaplasia (64.1 ± 30.0 PAS+ pixels/µm of basement membrane, Fig. 5b), which was attenuated by prophylactic IL-4Rα mAb blockade (3.0 ± 3.2 PAS+ pixels/µm of basement membrane). However, we failed to see a complete attenuation when anti-IL-4Rα mAb was administered after the induction of allergic airway inflammation (15.3 ± 8.1 PAS+ pixels/µm of basement membrane, Fig. 5c and d). We conclude that prophylactic IL-4Rα blockade is sufficient to ameliorate the major hallmarks of allergic airway inflammation.
IL-4Rα blockade reduces pH1N1 infection-induced weight loss in HDM-sensitized mice
To determine the role of IL-4Rα signalling in HDM-induced morbidity following pH1N1 infection, weight loss was monitored in IgG control mice and those receiving either a prophylactic or a therapeutic treatment of IL-4Rα mAb blockade. pH1N1-induced weight loss was attenuated by both the prophylactic (7.9 ± 6.9%, vs. 19.6 ± 4% in IgG control mice) and the therapeutic (14.3 ± 7.2%, vs. 22.6 ± 2% in IgG control mice) treatment strategies in HDM-sensitized mice on days 6–8 post-infection (Fig. 6a and b).
IL-4Rα blockade reduces viral load and pro-inflammatory cytokine concentration
To further explore the influence of IL-4Rα blockade on pH1NI-infected mice, viral loads were evaluated in the lungs of infected mice in the various treatment groups. Mice were sacrificed on day 8 post-infection, and qPCR was performed on homogenized lung tissue. HDM-sensitized mice demonstrated elevated copy numbers of the virus (106.5 ± 100.3 copies) compared with PBS exposed mice (105.7 ± 100.3 copies) (Fig. 7a). HDM-sensitized mice also demonstrated elevated levels of the pro-inflammatory cytokines IL-6 (Fig. 7d) and IFNγ-induced protein 10 (IP-10) (Fig. 7g) in plasma, but no differences were found in BALF (see Additional file 1: Figure E6A, D).
Administration of a mAb that blocks IL-4Rα signalling in HDM-sensitized mice induced a reduction in viral titres in both the prophylactic (105.8 ± 100.6 copies, vs. 107.1 ± 100.5 copies in IgG control mice) and therapeutic (106.4 ± 100.8 copies, vs. 107.7 ± 100.4 copies in IgG control mice) treatment groups (Fig. 7b, c). In addition, we observed a reduction in IL-6 (Fig. 7e–f) and IP-10 (Fig. 7h–i) protein levels in plasma and BALF (see Additional file 1: Figure E6B, C, E, F). We conclude that IL-4Rα mAb blockade reduces excessive viral burden associated with HDM-sensitization and the concentration of pro-inflammatory markers associated with asthma exacerbation.
Although the 2009 H1N1 pandemic affected a heterogeneous group of individuals, asthma was the most common risk factor leading to hospitalization and death [4, 5]. With over 300 million people worldwide suffering from asthma, new therapies are urgently needed to protect this vulnerable population from highly virulent influenza A infections . Using a murine model of allergic airway inflammation, we showed that prior HDM-sensitization results in greater pH1N1-induced morbidity (as measured by weight loss). Importantly, we demonstrated that prophylactic or therapeutic use of a mAb that blocks IL-4Rα signalling, a clinically approved intervention strategy for moderate to severe asthma, can reduce the severity of inflammation and pathology related to pH1N1 infection . Together, these observations support the concept that asthmatics have an augmented risk of morbidity and mortality related to pH1N1 infection, and that this can be abrogated through IL-4Rα-targeted immunotherapy.
To investigate the effect of IL-4Rα mAb intervention in the context of allergic sensitization and pH1N1 infection, we measured viral load and the innate antiviral response in a time-course manner. We found that HDM-sensitized mice demonstrated an elevated viral load on day 8 post-infection and this was associated with a downregulation in IFN-β and ISGs shortly after pH1N1 inoculation, on day 4 post-infection. These data suggest that a dampened induction of the host’s antiviral response leads to elevated viral loads as a contributor to increased morbidity observed in HDM-sensitized mice.
While previous murine studies have shown rapid weight loss in mice following pH1N1 infection, to the best of our knowledge, it has yet to be determined how allergic sensitization affects morbidity and mortality . House dust mite (Dermatophagoides pteronyssinus), an aeroallergen present in many households, is known to induce an allergic reaction in 85% of atopic patients . HDM sensitivity has been reported in up to 130 million people worldwide, and studies have identified HDM as an environmental trigger and a predictor for the development of persistent asthma [27,28,29]. Der p 1, the major protease constituent in HDM, can initiate an early pro-inflammatory response by inducing the release of IL-6 and IL-8 in the airways . Furthermore, HDM-induced inflammation in murine models results in disease and pathological phenotypes similar to those observed in human asthma. For example, HDM sensitization can induce GCM by promoting epithelial-mesenchymal transition, as well as eosinophilia through the induction of eotaxin release . Using repeated intranasal HDM instillations to create an allergic phenotype, we were able to closely mimic the human clinical findings from the 2009 H1N1 pandemic in a murine model of allergic asthma, and showed that HDM-sensitized mice experienced significantly greater morbidity (as measured by weight loss) following pH1N1 infection [4, 5].
Several studies have indicated that bronchial epithelial cells from asthmatic patients are defective in the production of the antiviral cytokine, IFN-β, and as a result, allow rapid viral replication in vitro [32,33,34]. Our results from the time-course study indicate that a dampened induction of IFN-β occurs early in HDM-sensitized mice, starting on day 4 post-infection. An attenuated IFN-β response limits the expression of key ISGs required for viral clearance, including MX1 and IFITM3, which prevent viral entry; OAS1 and ISG-15, which inhibit viral translation and replication; viperin, which inhibits viral budding and release; and RIG-I, which is a pattern recognition receptor that induces the transcription of IFN-β [34, 35]. This dampened induction of IFN-β and downstream ISGs likely permits rapid viral replication in vivo, leading to elevated viral loads observed on day 8 post-infection, which was accompanied by elevated concentrations of the pro-inflammatory cytokines, IL-6 and IP-10.
While Th2 immune responses drive asthma phenotypes including eosinophilia and mucous hyperplasia, there is evidence to suggest it may also increase susceptibility to viral exacerbations [13, 14]. For example, in an experimental rhinovirus infection model, lung function impairment and elevated viral loads in asthmatics subjects were associated with an augmented IL-4, IL-5, and IL-13 response . Murine asthma models have also shown that elevated IL-13 and dampened IFN-γ levels are associated with elevated viral loads and lung tissue destruction following pH1N1 infection . Our data indicate that HDM-sensitized mice exhibit elevated IL-4 and IL-5 levels at various time points throughout pH1N1 infection, and conversely, lower IFN-γ on day 6 post-infection.
Due to its ability to relay signals for both IL-4 and IL-13, the blockade of IL-4Rα signalling has been of interest for alleviating asthma symptoms and severity. Murine asthma models have demonstrated a significant reduction in airway goblet cell metaplasia and eosinophilia following IL-4Rα mAb blockade . Clinical trials using a human mAb targeting IL-4Rα have been successful in improving lung function and reducing peripheral blood eotaxin levels in moderate to severe eosinophilic asthma . However, the role of IL-4Rα blockade has yet to be investigated in reducing morbidity resulting from highly virulent influenza A infection. Using our model of HDM-sensitization and pH1N1 infection, mice were subjected to a mAb targeting murine IL-4Rα through a prophylactic as well as a therapeutic treatment strategy. Our findings indicate that prophylactic treatment with IL-4Rα mAb not only reduced asthma phenotypes such as airway goblet cell metaplasia and eosinophilia, but also improved disease severity by reducing weight loss and viral load. In the therapeutic regimen, blockade of IL-4Rα attenuated weight loss and reduced viral load though eosinophilia and goblet cell metaplasia persisted. The exact mechanism for this observation is not known. One possibility is that the therapeutic dose of the monoclonal antibody was insufficient to completely block eosinophilia in tissue. Another possibility is that the therapeutic dose was not given sufficiently long enough to reverse these histological changes. Interestingly, with the therapeutic regimen, we did observe a significant reduction in eotaxin levels, an earlier marker of eosinophil recruitment, demonstrating the efficacy of IL-4Rα blockade.
Our data indicate that allergic sensitization increases morbidity following pH1N1 infection by dampening anti-viral host defence pathways and increasing viral load and that prophylactic or therapeutic use of IL-4Rα blockade significantly improves disease expression and outcomes of mice sensitized to HDM. Together, these data suggest atopic asthmatics are at increased risk of severe influenza viral infections, which may be mitigated by therapeutic strategies involving IL-4Rα blockade.
Availability of data and materials
The primary data in this paper are available upon request to the senior author (D.D.S).
Analysis of variance
Bronchoalveolar lavage fluid
Formalin fixed paraffin-embedded
Goblet cell metaplasia
House dust mite
Interferon-gamma induced protein 10
Interferon stimulated gene
Influenza A virus pandemic strain subtype H1N1
Quantitative polymerase chain reaction
Standard error of the mean
T helper type 1 cellular response
T helper type 2 cellular response
Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687–95.
Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L, Atkins CY, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–April 2010). Clin Infect Dis. 2011. https://doi.org/10.1093/cid/ciq012.
Ozawa M, Kawaoka Y. Cross talk between animal and human influenza viruses. Annu Rev Anim Biosci. 2013;1:21–42.
Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med. 2009;361(20):1935–44.
Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med. 2011;8(7):5.
Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469–78.
Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001–2009. MMWR Morb Mortal Wkly Rep. 2011;60(17):547–52.
Prieto J, Lensmar C, Roquet A, van der Ploeg I, Gigliotti D, Eklund A, et al. Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. Respir Med. 2000;94(8):806–14.
Brightling CE, Symon FA, Birring SS, Bradding P, Pavord ID, Wardlaw AJ. TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J Allergy Clin Immunol. 2002;110(6):899–905.
Truyen E, Coteur L, Dilissen E, Overbergh L, Dupont LJ, Ceuppens JL, et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax. 2006;61(3):202–8.
Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol. 2008;121(3):685–91.
Backman H, Raisanen P, Hedman L, Stridsman C, Andersson M, Lindberg A, et al. Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016-results from three population surveys. Clin Exp Allergy. 2017;47(11):1426–35.
Hirst SJ, Hallsworth MP, Peng Q, Lee TH. Selective induction of eotaxin release by interleukin-13 or interleukin-4 in human airway smooth muscle cells is synergistic with interleukin-1beta and is mediated by the interleukin-4 receptor alpha-chain. Am J Respir Crit Care Med. 2002;165(8):1161–71.
Zuyderduyn S, Ninaber DK, Schrumpf JA, van Sterkenburg MA, Verhoosel RM, Prins FA, et al. IL-4 and IL-13 exposure during mucociliary differentiation of bronchial epithelial cells increases antimicrobial activity and expression of antimicrobial peptides. Respir Res. 2011;12(59):1465–9921.
Kasaian MT, Marquette K, Fish S, DeClercq C, Agostinelli R, Cook TA, et al. An IL-4/IL-13 dual antagonist reduces lung inflammation, airway hyperresponsiveness, and IgE production in mice. Am J Respir Cell Mol Biol. 2013;49(1):37–46.
Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebadze T, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A. 2008;105(36):13562–7.
Ravanetti L, Dijkhuis A, Dekker T, Sabogal Pineros YS, Ravi A, Dierdorp BS, et al. IL-33 drives influenza-induced asthma exacerbations by halting innate and adaptive antiviral immunity. J Allergy Clin Immunol. 2019;143(4):1355–70.
Andrews AL, Holloway JW, Holgate ST, Davies DE. IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Immunol. 2006;176(12):7456–61.
Hirota JA, Budelsky A, Smith D, Lipsky B, Ellis R, Xiang YY, et al. The role of interleukin-4Ralpha in the induction of glutamic acid decarboxylase in airway epithelium following acute house dust mite exposure. Clin Exp Allergy. 2010;40(5):820–30.
Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–66.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96.
Brandt EB, Munitz A, Orekov T, Mingler MK, McBride M, Finkelman FD, et al. Targeting IL-4/IL-13 signaling to alleviate oral allergen-induced diarrhea. J Allergy Clin Immunol. 2009;123(1):53–8.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.
Tam A, Hughes M, McNagny KM, Obeidat M, Hackett TL, Leung JM, et al. Hedgehog signaling in the airway epithelium of patients with chronic obstructive pulmonary disease. Sci Rep. 2019;9(1):3353.
Tam A, Tanabe N, Churg A, Wright JL, Hogg JC, Sin DD. Sex differences in lymphoid follicles in COPD airways. Respir Res. 2020;21(1):46.
Paquette SG, Banner D, Zhao Z, Fang Y, Huang SS, Leomicronn AJ, et al. Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection. PLoS ONE. 2012;7(6):5.
Calderon MA, Linneberg A, Kleine-Tebbe J, De Blay F, Hernandez Fernandez de Rojas D, Virchow JC, et al. Respiratory allergy caused by house dust mites: What do we really know? J Allergy Clin Immunol. 2015;136(1):38–48.
Llanora GV, Ming LJ, Wei LM, van Bever HP. House dust mite sensitization in toddlers predict persistent wheeze in children between eight to fourteen years old. Asia Pacific Allergy. 2012;2(3):181–6.
Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47–56.
Kauffman HF, Tamm M, Timmerman JAB, Borger P. House dust mite major allergens Der p 1 and Der p 5 activate human airway-derived epithelial cells by protease-dependent and protease-independent mechanisms. Clin Mol Allergy CMA. 2006;4:5.
Gandhi VD, Davidson C, Asaduzzaman M, Nahirney D, Vliagoftis H. House dust mite interactions with airway epithelium: role in allergic airway inflammation. Curr Allergy Asthma Rep. 2013;13(3):262–70.
Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–47.
Johnston SL. Innate immunity in the pathogenesis of virus-induced asthma exacerbations. Proc Am Thorac Soc. 2007;4(3):267–70.
Akbarshahi H, Menzel M, Ramu S, Mahmutovic Persson I, Bjermer L, Uller L. House dust mite impairs antiviral response in asthma exacerbation models through its effects on TLR3. Allergy. 2018;73(5):1053–63.
Okada S, Hasegawa S, Hasegawa H, Ainai A, Atsuta R, Ikemoto K, et al. Analysis of bronchoalveolar lavage fluid in a mouse model of bronchial asthma and H1N1 2009 infection. Cytokine. 2013;63(2):194–200.
We are grateful for the technical support and advice from Dr. Konosuke Moritani, and Dr. Takeyuki Wada. We also thank Amgen (Seattle, WA) for providing the reagents used in this study.
This work was funded by the Canadian Institutes of Health Research (#332196). The funder had no role in the design of the study, data collection, data analysis or decision to publish.
Ethics approval and consent to participate
All experiments were approved by the Animal Care and Biosafety Committees of the University of British Columbia (Research Ethics Board #A16-0331).
The authors have declared that no conflict of interest exists. Kimia Shahangian is an employee of STEMCELL Technologies. Kimia was a graduate student at the University of British Columbia when this work was performed and had no affiliation with STEMCELL at the time.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
. Primers used for qPCR assays. Figure E1. Lung Tissue Sectioning. The left lung was cut in a transverse manner to create a superior and an inferior segment. The inferior segment was embedded into paraffin, while the superior segment was further cut in a sagittal manner and embedded. Figure E2. House dust mite (HDM) sensitization delays viral clearance. Phosphate-buffered saline (PBS)-exposed or HDM-sensitized mice were infected with pandemic H1N1 (pH1N1) and sacrificed on days 0, 2, 4, 6, and 8 post-infection. (A) IFN-β protein expression was determined using ELISA on the supernatant of bronchoalveolar lavage fluid (BALF). (B) qPCR was performed on RNA from homogenized lung tissue to determine the number of viral RNA copies, and results were compared using a two-tailed Student’s t-test. Data (n=5 per group per day) were compared using a two-way ANOVA with Sidak’s multiple comparison’s test and are expressed as mean ± SEM. *P<0.05 after correction for multiple comparisons; ns: not significant. Figure E3. House dust mite (HDM) sensitization dampens the induction of interferon stimulated genes (ISGs). Phosphate-buffered saline (PBS)-exposed or HDM-sensitized mice were infected with pandemic H1N1 (pH1N1) and sacrificed on days 0, 2, 4, 6, and 8 post-infection. qPCR was performed on RNA from homogenized lung tissue to measure the gene expression of the interferon stimulated genes (A) MX1, (B) IFITM3, (C) OAS1, (D) ISG15, (E) Viperin, and (F) RIG-I. Results were normalized to expression on day 0 and were compared using a Mann-Whitney U test. Data (n=5 per group per day) are expressed as mean ± SEM. *P<0.05 after correction for multiple comparisons; **p<0.01 after correction for multiple comparisons; ns: not significant. Figure E4. House dust mite (HDM)-sensitized mice present elevated IL-33 and lower IFN-γ levels following pandemic H1N1 (pH1N1) infection. Phosphate-buffered saline (PBS)-exposed or HDM-sensitized mice were infected with pandemic H1N1 (pH1N1) and sacrificed through a time-course study. (A) IL-33 and (B) IFN-γ protein levels were measured using ELISA and multiplex assay, respectively (n=5 per group per day). Data were compared using two-way ANOVA with Sidak’s multiple comparison’s test and are expressed as mean ± SEM. *P<0.05 after correction for multiple comparisons; ** P<0.01 after correction for multiple comparisons; ns: not significant. Figure E5. Bronchoalveolar lavage fluid (BALF) cell differential analysis. BALF was obtained on day 8 post-infection from pandemic H1N1 (pH1N1)-infected mice. The percentage of (A-C) neutrophils, (D-F) lymphocytes, and (G-I) macrophages was determined in a total of 200 counted cells. (J-L) Trypan blue was used on the re-suspended BALF pellet and the absolute number of inflammatory cells in BALF was determined using a hemocytometer. Data were compared using a two-tailed Student’s t-test and are expressed as mean ± SEM. Blue/pink: intranasal phosphate-buffered saline (PBS) (n=10) / intranasal house dust mite extract (HDM) (n=9); green/orange: intranasal HDM followed by prophylactic strategy of IL-4Rα blockade (n=12) / IgG (n=12); black/red: intranasal HDM followed by therapeutic strategy of IL-4Rα blockade (n=12) / IgG (n=10). ** P<0.01; ***P<0.001; ns: not significant. Figure E6. Systemic blockade of Interleukin-4 receptor alpha (IL-4Rα) reduces IL-6 and IP-10 levels in bronchoalveolar lavage fluid (BALF). BALF was obtained on day 8 post-infection from pandemic H1N1 (pH1N1)-infected mice. (A-C) IL-6 and (D-F) IP-10 protein levels were measured in BALF by multiplex assay. Data were compared using the Mann-Whitney U test and are expressed as mean ± SEM. Blue/pink: intranasal phosphate-buffered saline (PBS) (n=10) / intranasal house dust mite extract (HDM) (n=9); green/orange: intranasal HDM followed by prophylactic strategy of IL-4Rα blockade (n=13) / IgG (n=12); black/red: intranasal HDM followed by therapeutic strategy of IL-4Rα blockade (n=12) / IgG (n=12). * P<0.05; ** P<0.01; ns: not significant. Figure E7. HDM-sensitization Induces Immune Cell Infiltration to the Airways. (A) PBS-exposed or HDM-sensitized mice were sacrificed on day 8 following pH1N1 infection or CAF exposure (n=10 except for HDM + pH1N1 n=9). Paraffin-embedded lung tissue obtained from these mice was sectioned and stained with Periodic Acid Schiff (PAS). Fractional lymphoid area was quantified and is expressed as a percentage of lymphoid tissue area per total cross sectional area. Data are expressed as mean ± SEM by one-way ANOVA. (B) PBS-exposed or HDM-sensitized nice were sacrificed through a time-course study (n=5 per group per day). The lungs were homogenized with PBS, and the supernatant was collected for protein analysis using the BCA assay). Data are expressed as mean ± SEM by a two-way ANOVA with Sidak’s multiple comparisons test. ** P<0.01; *** P<0.001.
About this article
Cite this article
Shahangian, K., Ngan, D.A., Chen, H.H.R. et al. IL-4Rα blockade reduces influenza-associated morbidity in a murine model of allergic asthma. Respir Res 22, 75 (2021). https://doi.org/10.1186/s12931-021-01669-0